IL-32 subsequently activates the β5-integrin-Src-Akt pathway to reduce the sensitivity to the third-generation tyrosine kinase inhibitors (TKIs) in EGFR mutated lung cancer patients (158). This evidence concerns the gene AKT1 and lung cancer.